Dolby Laboratories

As of June 30, 2026, Dolby Laboratories carries a market capitalization of 4.92B, placing it among publicly traded companies globally. Its enterprise value stands at 4.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Dolby Laboratories's next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Dolby Laboratories has 93.65M shares outstanding.

As of June 30, 2026, Dolby Laboratories trades at a trailing price-to-earnings ratio of 22.12. The price-to-sales ratio is 3.69, and the price-to-book ratio stands at 1.91.

As of June 30, 2026, Dolby Laboratories trades at an EV/EBITDA multiple of 12.59 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.03 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Dolby Laboratories trades at an EV/FCF ratio of 12.31, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 4.31B versus a market cap of 4.92B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Dolby Laboratories maintains a current ratio of 3.19, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Dolby Laboratories posted a return on equity (ROE) of 8.72, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.46 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.12, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.48, useful for judging operating efficiency across full business cycles. The company generates approximately 660,338.86 in revenue per employee across its workforce of 2,051.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.31 indicates how many times Dolby Laboratories sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Dolby Laboratories recorded 48.77M in income tax expense. That works out to an effective tax rate of 17.62, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 276.77M, leaving 226.18M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Dolby Laboratories's stock has declined approximately 5.83% over the past 52 weeks. The 50-day moving average sits at 60.76, while the 200-day moving average is 59.32.

Over the twelve months ended June 30, 2026, Dolby Laboratories generated 1.35B in revenue and converted that into 226.18M in net income, yielding earnings per share of 2.38. EBITDA reached 342.41M, while operating income came in at 261.83M.

As of June 30, 2026, Dolby Laboratories holds 670.05M in cash and equivalents against 47.45M in total debt, resulting in a net debt position of -669.39M. Total book value stands at 2.58B, with working capital of 909.71M providing operational flexibility.

Dolby Laboratories produced 437.60M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -87.50M in capital expenditures, free cash flow totaled 350.10M - equivalent to 3.68 per share.

Over the twelve months ended June 30, 2026, Dolby Laboratories posted a gross margin of 87.61, reflecting its pricing power and cost economics. The operating margin of 19.33 and net profit margin of 16.70 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Dolby Laboratories paid dividends of 1.41 per share. The dividend payout ratio of 58.41 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 6.95, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 7.65, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Dolby Laboratories shareholders.

As of June 30, 2026, Dolby Laboratories has an Altman Z-Score of 8.33, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.